Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
J Surg Oncol. 2013 Dec;108(7):481-5. doi: 10.1002/jso.23424. Epub 2013 Sep 9.
The aim of this study was to determine whether the combined use of the C-reactive protein (CRP) level and neutrophil-lymphocyte ratio (NLR) before treatment predicts disease-specific survival in adult patients with soft tissue sarcoma (STS).
We retrospectively reviewed 142 patients who presented with STS between 1995 and 2010.
The NLR varied from 0.54 to 7.59. An elevated CRP level was observed in 36 patients before treatment. The patients with both an elevated CRP level and high NLR had a poorer disease-specific survival (46% at 5 years) than the patients with both a normal CRP level and low NLR (87% at 5 years) (P = 0.0005). The patients with both an elevated CRP level and high NLR also had a poorer disease-specific survival than the patients with either an elevated CRP level or high NLR (75.6% at five years) (P = 0.03). There were no significantly prognostic differences between the patients with a normal CRP level and low NLR and those with either an elevated CRP level or high NLR (P = 0.18). A multivariate analysis also showed the preoperative NLR and CRP level to be independent predictors of survival.
We recommend the routine measurement of these markers to identify patients with a greater risk of death.
本研究旨在确定治疗前 C 反应蛋白(CRP)水平和中性粒细胞-淋巴细胞比值(NLR)的联合使用是否可以预测成人软组织肉瘤(STS)患者的疾病特异性生存。
我们回顾性分析了 1995 年至 2010 年间就诊的 142 例 STS 患者。
NLR 从 0.54 到 7.59 不等。36 例患者治疗前 CRP 水平升高。与 CRP 水平正常且 NLR 较低的患者(5 年生存率为 87%)相比,CRP 水平升高且 NLR 较高的患者疾病特异性生存率(5 年生存率为 46%)更差(P=0.0005)。CRP 水平升高且 NLR 较高的患者的疾病特异性生存率也明显低于 CRP 水平升高或 NLR 较高的患者(5 年生存率为 75.6%)(P=0.03)。CRP 水平正常且 NLR 较低的患者与 CRP 水平升高或 NLR 较高的患者之间的预后差异无统计学意义(P=0.18)。多变量分析也显示术前 NLR 和 CRP 水平是生存的独立预测因子。
我们建议常规测量这些标志物,以识别具有更高死亡风险的患者。